- Home
- NUVL vs KRG Comparison
NUVL vs KRG Comparison
Compare NUVL & KRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- KRG
- Stock Information
- Founded
- NUVL 2017
- KRG 1971
- Country
- NUVL United States
- KRG United States
- Employees
- NUVL N/A
- KRG N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- KRG Real Estate Investment Trusts
- Sector
- NUVL Health Care
- KRG Real Estate
- Exchange
- NUVL Nasdaq
- KRG Nasdaq
- Market Cap
- NUVL 5.6B
- KRG 5.0B
- IPO Year
- NUVL 2021
- KRG 2004
- Fundamental
- Price
- NUVL $75.00
- KRG $22.69
- Analyst Decision
- NUVL Strong Buy
- KRG Buy
- Analyst Count
- NUVL 8
- KRG 7
- Target Price
- NUVL $115.50
- KRG $27.71
- AVG Volume (30 Days)
- NUVL 452.9K
- KRG 1.4M
- Earning Date
- NUVL 08-07-2025
- KRG 07-29-2025
- Dividend Yield
- NUVL N/A
- KRG 4.74%
- EPS Growth
- NUVL N/A
- KRG N/A
- EPS
- NUVL N/A
- KRG 0.06
- Revenue
- NUVL N/A
- KRG $856,165,000.00
- Revenue This Year
- NUVL N/A
- KRG $3.11
- Revenue Next Year
- NUVL N/A
- KRG $3.08
- P/E Ratio
- NUVL N/A
- KRG $366.89
- Revenue Growth
- NUVL N/A
- KRG 3.94
- 52 Week Low
- NUVL $55.54
- KRG $18.52
- 52 Week High
- NUVL $113.51
- KRG $28.24
- Technical
- Relative Strength Index (RSI)
- NUVL 48.73
- KRG 56.62
- Support Level
- NUVL $76.42
- KRG $22.16
- Resistance Level
- NUVL $78.94
- KRG $22.54
- Average True Range (ATR)
- NUVL 2.71
- KRG 0.40
- MACD
- NUVL -0.34
- KRG 0.02
- Stochastic Oscillator
- NUVL 31.73
- KRG 74.60
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.